Vyome Holdings, Inc. (HIND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vyome Holdings, Inc. (HIND) has a cash flow conversion efficiency ratio of 1.108x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.34 Million) by net assets ($3.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Vyome Holdings, Inc. (HIND) balance sheet quality index to measure how much of total assets are equity-financed.
Vyome Holdings, Inc. - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how Vyome Holdings, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check HIND cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Vyome Holdings, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vyome Holdings, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kalo Gold Corp
NASDAQ:KLGDD
|
-2.311x |
|
HF Company SA
PA:ALHF
|
0.038x |
|
Fevertree Drinks Plc
LSE:FEVR
|
0.095x |
|
SSH Group Ltd
AU:SSH
|
0.196x |
|
Malaysian Genomics Resource
KLSE:0155
|
0.005x |
|
GRAFT POLYMER UK LS -001
F:J4I
|
-0.021x |
|
TALKPOOL AG SF-05
F:TKPL
|
-0.130x |
|
Grand Pacific Petrochemical Corp Pref
TW:1312A
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Vyome Holdings, Inc. (2005–2024)
The table below shows the annual cash flow conversion efficiency of Vyome Holdings, Inc. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Vyome Holdings, Inc..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-253.00K | $-4.43 Million | 17.498x | +787.44% |
| 2023-12-31 | $6.66 Million | $-16.96 Million | -2.545x | +57.45% |
| 2022-12-31 | $3.66 Million | $-21.90 Million | -5.983x | -1625.07% |
| 2021-12-31 | $44.33 Million | $-15.38 Million | -0.347x | +41.23% |
| 2020-12-31 | $14.49 Million | $-8.55 Million | -0.590x | -0.19% |
| 2019-12-31 | $24.11 Million | $-14.20 Million | -0.589x | +32.16% |
| 2018-12-31 | $31.66 Million | $-27.49 Million | -0.868x | -169.66% |
| 2017-12-31 | $76.37 Million | $-24.59 Million | -0.322x | +95.42% |
| 2016-12-31 | $2.94 Million | $-20.66 Million | -7.028x | -14.19% |
| 2015-12-31 | $3.67 Million | $-22.61 Million | -6.155x | -111.59% |
| 2014-12-31 | $6.66 Million | $-19.38 Million | -2.909x | -131.72% |
| 2013-12-31 | $14.68 Million | $-18.43 Million | -1.255x | +33.69% |
| 2012-12-31 | $11.88 Million | $-22.48 Million | -1.893x | -90.30% |
| 2011-12-31 | $20.04 Million | $-19.94 Million | -0.995x | -116.26% |
| 2010-12-31 | $29.71 Million | $-13.66 Million | -0.460x | +89.59% |
| 2009-12-31 | $5.58 Million | $-24.66 Million | -4.418x | -49.66% |
| 2008-12-31 | $11.41 Million | $-33.67 Million | -2.952x | -472.02% |
| 2007-12-31 | $45.28 Million | $-23.37 Million | -0.516x | +9.13% |
| 2006-12-31 | $28.57 Million | $-16.23 Million | -0.568x | +89.09% |
| 2005-12-31 | $1.97 Million | $-10.28 Million | -5.205x | -- |
About Vyome Holdings, Inc.
Vyome Holdings Inc., a clinical-stage healthcare company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States and global markets. The company was founded in 2017 and is based in Cambridge, Massachusetts.